&w=3840&q=100)
What rising blood pressure means for your health, and what to do about it
High blood pressure, also known as hypertension, is often called a silent killer. It causes over 12.8 per cent of all deaths globally, according to WHO. You may feel perfectly fine, yet your blood vessels could be under constant strain, increasing the risk of heart disease, stroke, and other serious complications.
How is blood pressure measured?
Blood pressure is the force of your blood pushing against the walls of your arteries. It's measured using two numbers:
A normal reading is typically around 120/80 mmHg.
What causes high blood pressure?
Dr Ajith Pillai, Chief Cardiologist at Kauvery Hospital, Chennai, explains that hypertension may develop over time due to:
Obesity and poor diet (especially high salt intake)
Stress and lack of physical activity
Smoking and alcohol use
Chronic diseases like diabetes and kidney conditions
Hormonal issues or sleep apnoea
Family history of hypertension
Primary hypertension has no identifiable cause, while secondary hypertension stems from other conditions.
Why is hypertension awareness so important?
A 2023 Indian Journal of Public Health study shows:
24–30% of urban Indians and 12–14% of rural population have hypertension
Hypertension causes 54% of strokes and 47% of heart disease cases globally
By 2030, it may lead to 12.5 million deaths annually
Dr Pillai noted: 'Only 1 in 3 people are diagnosed, and less than 1 in 5 are treated effectively. Resistant hypertension needs urgent attention.'
What symptoms should you watch out for?
Often, hypertension is symptomless. But some people may experience:
Headaches or dizziness
Nosebleeds and blurry vision
Abnormal heart rhythms
Shortness of breath or buzzing in ears
Resistant hypertension, when BP remains high despite three or more medications, requires specialised care.
Can you prevent high blood pressure?
WHO recommends:
A diet rich in fruits, vegetables, and whole grains
Lower salt and sugar intake
At least 30 minutes of physical activity most days
Quitting smoking and limiting alcohol
Managing stress with meditation or therapy
What are the treatment options for high BP?
Management may include:
Lifestyle changes
Regular BP monitoring
Medication such as ACE inhibitors, beta blockers, ARBs, calcium channel blockers, and diuretics
Monthly medication costs: ₹100–₹1,000 depending on the brand.
For resistant hypertension, newer options like renal denervation (RDN) offer hope.
What about low blood pressure?
Low blood pressure (hypotension) is defined as readings below 90/60 mmHg. While some live with it without symptoms, others may face:
Dizziness, fainting, or nausea
Blurred vision
Cold, clammy skin
Fatigue
What causes hypotension?
Dehydration or prolonged bed rest
Certain medications
Heart or hormonal disorders
Pregnancy or low blood volume
Managing low BP includes:
Staying hydrated
Eating smaller meals more frequently
Increasing salt (under doctor's advice)
Wearing compression stockings
Adjusting medication
Monthly management cost: ₹50–₹300, possibly more with hospitalisation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
5 minutes ago
- Indian Express
How new ICMR vaccine gives new hope in fight against malaria
The Indian Council of Medical Research (ICMR) has announced a promising candidate vaccine for malaria, which it will now further develop, test and manufacture for commercial purposes in partnership with private companies. Known as AdFalciVax, the vaccine mainly targets two parts of Plasmodium falciparum, a pathogen that is the most common source of malaria in humans. In India, however, the disease is caused by Plasmodium vivax against which AdFalciVax is ineffective. Malaria is a parasitic infection transmitted by mosquitoes, typically causing symptoms such as fever, chills, night sweats, nausea, vomiting, and diarrhoea. In some cases, it can lead to severe complications such as seizures, fluid in the lungs, organ damage, and death. Having claimed millions of lives, malaria has been one of the deadliest diseases in human history. Currently, the disease kills about four lakh people annually, according to World Health Organization (WHO) figures. Malaria is most endemic in Africa — Nigeria, Congo, Tanzania, Mozambique, Niger, and Burkina Faso together account for more than half the yearly deaths. The disease is also present in India, although malaria deaths have sharply reduced in the country in recent years. According to the National Vector Borne Disease Control Programme (NVBDCP), reported malaria deaths stood at 1,151in 1995, and came down to only 93 in 2020 and 83 in 2022. Note that these figures are much lower than the numbers provided annually by the WHO. The organisation's 'World Malaria Report' says there were 5,511 deaths due to the disease in India in 2022. This discrepancy is due to WHO providing estimates and NVBDCP providing only the number of confirmed deaths, which may not have been officially reported. To combat malaria, scientists have been working to develop a vaccine for decades but with limited success. Recently, two vaccines—RTS,S and R21—were approved for use, but their efficacy, at 75%, is quite low. That's why the announcement about ICMR's candidate vaccine has given new hope in the fight against the disease. AdFalciVax is a chimeric recombinant vaccine — a type of vaccine that uses different parts of the genes of a pathogen (in this case, Plasmodium) to create target proteins that trigger an immune response after being injected. AdFalciVax uses two types of target proteins to prevent the spread of infection in two different ways. n It uses the circumsporozoite protein (CSP) to prevent infection in the person who has been immunised. The CSP is produced during the sporozoite stage (when a parasite can infect a new host) and the liver stage (when a parasite enters liver cells, multiplies, and then infects red blood cells) of the parasite. Subhash Singh, project manager for development of the vaccine at the ICMR-Regional Medical Research Centre, Bhubaneswar, told The Indian Express: 'Any immune response generated against these stages protects the immunised person from getting the infection.' n The vaccine also uses the Pro6C protein, a fusion of parts of two different proteins — Pfs230 and Pfs48/45 — produced by Plasmodium falciparum. This protein prevents the spread of infection in the community. 'The Pro6C protein… stops further spread of the disease by disrupting the lifecycle of the pathogen. It disrupts the development of the parasite in the midgut of a mosquito preventing further transmission,' Singh said. Unlike AdFalciVax, RTS,S and R21 only use the CSP protein, and can prevent infection only in vaccinated persons. Unlike AdFalciVax, RTS,S and R21 vaccines also do not use full-length CSP proteins. This is why the ICMR's candidate vaccine is 'likely to produce a stronger immune response and better protect against infection,' according to Singh. Researchers have found that AdFalciVax provided more than 90% protection against infection in mice. The candidate vaccine has yet to undergo rigorous human trials, and the preliminary results have been obtained only through testing on animals. Studies have also suggested that AdFalciVax produces an immune response that may last longer than that produced by the other two vaccines. Singh said: 'One of the challenges of existing vaccines is that the immune response is short-lived. People need a fifth booster shot even after four primary doses. We do not know how this will work in humans, but preliminary indications show that three doses of the ICMR candidate vaccine produced robust protection against infection in mice for more than three months. This roughly translates to a decade in human life.' AdFalciVax also contains an adjuvant — a substance used in vaccines to boost the body's immune response against the targeted disease — called alum. Singh says the use of alum is beneficial as it does not pose a risk of causing chronic inflammation, unlike adjuvants such as AS01 and Matrix M, which are used in RTS,S and R21. Alum is also known to be reliable, and has been used in numerous vaccines used in childhood immunisation programs over the years. Another advantage is that alum in AdFalciVax can remain stable at room temperature for at least nine months, according to initial studies. This might make it possible to 'transport the vaccines without maintaining the cold chain,' Singh said. The ICMR wants to partner with a company that can further develop its candidate vaccine, carry out human clinical trials, and scale up for commercial production. Although the ICMR will share the technology of developing AdFalciVax with the chosen company, it will continue to hold the intellectual property rights. Any intellectual property rights generated during the collaboration will be held jointly by the ICMR and the company. The ICMR will also earn 2% royalty on any sales of the vaccine. Authors from both the company and the ICMR will be credited in any research papers generated, and all data will be jointly owned.
Indian Express
35 minutes ago
- Indian Express
Obesity is even worse for health than believed earlier. India can't ignore that
While we continue to battle malnutrition in many communities, a silent epidemic is spreading through our households — one that carries far graver consequences. Obesity, once considered a problem of the affluent, is now clustering within Indian families at an alarming rate, and with it comes a hidden threat that policymakers can no longer ignore: Cancer. Recent national data paint a disturbing picture of India's nutritional transition. Nearly 20 per cent of Indian households now have all adult members classified as overweight, while 10 per cent have all adults classified as obese. This suggests shared environmental and behavioural factors. In states like Tamil Nadu and Punjab, two out of every five households have all adults classified as obese. Urban areas show clustering rates which are double those of rural areas, conveying a clear picture of how prosperity and urbanisation are transforming India's health landscape. What makes this particularly concerning is its transgenerational nature. When obesity clusters within households, children grow up in environments that normalise unhealthy dietary patterns and sedentary lifestyles, creating cycles of risk that transcend generations. The evidence linking obesity to cancer is overwhelming. The WHO's International Agency for Research on Cancer (IARC) has classified excess body weight as a significant risk for cancer. Obesity is directly associated with at least 13 types of cancer: Colorectal, breast (postmenopausal), endometrial, kidney, liver, pancreatic, ovarian, thyroid, meningioma, multiple myeloma, adenocarcinoma of the esophagus, gastric cardia, and gallbladder cancers. An IARC study, published in 2023, the largest of its kind, showed that having a high body mass index increases cancer risk by 17 per cent for people who also have cardiovascular diseases. The American Cancer Society estimates that excess body weight accounts for about 11 per cent of cancers in women and 5 per cent in men in the US. The biological pathways are clear. Hyperinsulinemia — chronically elevated insulin levels and insulin resistance — promotes obesity and diabetes. Insulin is also a growth factor and when chronically elevated, it can drive malignant transformation. Chronic inflammation associated with obesity represents another deadly pathway. Excess body fat cells (adipocytes) produce inflammatory factors, creating a state of chronic low-grade inflammation that damages DNA and interferes with immune surveillance — our body's natural defence system against cancer. Hormonal disruption adds another layer of risk. Fat tissue produces excess estrogen, and dramatically increases risks for hormone-sensitive breast and endometrial cancers. Cardio-metabolic dysfunction completes this deadly quartet. Hyperinsulinemia/ insulin resistance and altered glucose metabolism in the run-up to obesity creates a metabolic/inflammatory environment that favours development of cancer cells, their rapid growth and metastasis. India's situation is particularly precarious because we face this obesity epidemic alongside existing healthcare challenges. The economic implications for patients are staggering, too. Cancer treatment can devastate families financially, and when obesity-related cancers strike multiple household members — as clustering patterns suggest they might — the economic burden can be catastrophic. Prevention, therefore, isn't just a health imperative; it's an economic necessity. The household clustering of obesity presents both a challenge and an opportunity. Rather than treating obesity as an individual's problem, we must recognise it as a health problem that requires targeting the family as a unit for intervention. The government's recent commitment to establishing Day Care Cancer Centres in all district hospitals over the next three years, with 200 centres planned for 2025-26, provides a crucial foundation. However, these centres must prioritise prevention alongside treatment. We must scale up existing programmes like the National Programme for Prevention and Control of Non-Communicable Diseases to specifically target high-risk households and individuals. The data show we need concentrated efforts in southern states, urban areas, and affluent households. Regulatory interventions have proved effective globally — implementing taxes on sugary beverages, mandating front-of-pack nutrition labelling, and restricting marketing of ultra-processed foods. Obesity prevention programmes should target entire households, teaching families to shop for healthier ingredients; prepare meals at home consisting of fresh vegetables, leafy greens, whole grains and fruits; and engage in physical activities as a unit. Workplace and school-based nutrition programmes can break the cycle by creating healthy food environments outside the home. These behaviours can dramatically transform household practices reversing altered metabolic pathways and cardio-metabolic risk factors in a matter of days and weeks. However, it is crucial to understand that exercise alone cannot undo the harms of unhealthy food intake. While physical activity is essential for overall health, the metabolic damage from ultra-processed foods, excess sugar, poor dietary and inadequate sleep patterns cannot be 'burned off' through exercise. Poor nutrition requires dietary intervention, with exercise as a vital but complementary component. Our cities must become laboratories for obesity prevention. This means creating walkable neighbourhoods, ensuring access to affordable fresh farm produce, and designing urban/ work spaces that encourage physical activity rather than sedentary lifestyles. India's obesity crisis is not a distant threat — it's a present reality. Instituting practices to prevent obesity today mean preventing cancer tomorrow. The issue isn't whether we can afford to implement comprehensive obesity prevention strategies but whether we can afford not to do so. Our families, our healthcare system, and our economic future depend on the choices we make now. Shalini Singh is director, and Prashant Kumar Singh is senior scientist, ICMR-National Institute of Cancer Prevention and Research, Noida
Indian Express
35 minutes ago
- Indian Express
Breaking the TB chain
With the aim of making clinical testing for a wider range of diseases more accessible, the Indian Council of Medical Research (ICMR) has updated its National List of Essential Diagnostics to include rapid diagnostic tests for sickle cell anaemia, thalassaemia, Hepatitis B and syphilis, among others. Significantly, there is a push for early detection of tuberculosis (TB) at the lower levels of the healthcare system — the list recommends collecting samples at the level of the sub health centre (SHC) for molecular TB testing in order to identify asymptomatic individuals, as well as the TB skin test in community healthcare centres, to detect the presence of the pathogen in those without an active infection. WHO data shows that since 2015, India has made good progress in tackling TB. There has been a 17 per cent drop in the number of reported cases and a 20 per cent drop in the number of deaths. More than 85 per cent of those detected with the infection have received treatment and efforts to contain multi-drug-resistant TB are yielding results. It is evident that the TB problem is not intractable, but given India's massive disease burden, accounting for 27 per cent of the global cases, there is no room for complacency. The challenge is compounded by the problem of subclinical TB, where infected individuals do not yet present symptoms like persistent coughing. A study published in The International Journal of Tuberculosis and Lung Disease in 2024 found that 39 per cent of TB cases in India are subclinical, and therefore more likely to escape detection and continue spreading. This is why the attempt to tackle TB as early as possible matters. The ICMR's update, making molecular TB testing available at the level of the community health centre (CHC) —with sub-centres and primary healthcare centres (PHCs) also sending samples to be tested — could be crucial to providing timely treatment and breaking the chain of transmission. Despite making significant progress, India is unlikely to meet its target of eliminating TB by the end of the year. The government has made the expansion of primary healthcare a key pillar of its policy, with the aim of bringing a broad spectrum of services closer to the people through the network of over 1.7 lakh centres around the country. The broadening of the TB diagnostics must be factored in, equipping SHCs and PHCs to identify and treat infected individuals as early as possible, even as initiatives to reduce the financial burden of treatment and improve access to nutrition are strengthened.
